Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...

Small deep value individual investor, with a modest private investment portfolio, split approx. 50%-50% between shares and call options. I have a B.Sc. in aeronautical engineering and over 6 years of experience as an engineering consultant in the aerospace sector. The latter statement is not relevant in any way whatsoever to my investment style, but I thought to add it for self-indulgent purposes. I have a contrarian investment style, highly risky, and often dealing with illiquid options. How illiquid? Well ...

Group 1 - Elanco Animal Health announced the sale of future tiered royalties and commercial milestones related to Xdemvy for $295 million in cash, aimed at accelerating debt reduction [1] - The proceeds from the sale will help Elanco achieve a net leverage ratio of 3.9x to 4.3x adjusted EBITDA by the end of 2025 [1] - Elanco plans to repay portions of its outstanding term loans, which is expected to reduce interest expenses by approximately $10 million [2] Group 2 - Xdemvy, the first lotilaner-based product approved for human use, addresses Demodex blepharitis and is licensed to Tarsus Pharmaceuticals for exploration of human health applications [3] - The agreement covers tiered royalties on Xdemvy's U.S. net sales from April 2025 through August 2033 [3] - Elanco retains rights to all royalty payments on net sales outside the U.S. and any future human applications of lotilaner beyond ophthalmic solutions [4] Group 3 - Elanco is scheduled to release its Q1 2025 financial results, with analysts expecting adjusted earnings per share of 31 cents and sales of $1.21 billion [4] - The current stock price of Elanco is $9.75, which is below the 200-day moving average of $12.34, indicating potential bearish sentiment [6] - Recent trading saw Elanco's stock decrease by 1.03% to $9.65 [7]

Core Viewpoint - McDonald's Corp is set to report its first-quarter earnings, with Wall Street expecting an EPS of $2.66 and revenues of $6.09 billion, indicating strong market anticipation for the results [1]. Group 1: Stock Performance - McDonald's stock has increased by 16.11% over the past year and 8.38% year-to-date, reflecting positive investor sentiment [1]. - The current stock price is $317.62, which is above the eight-day simple moving average (SMA) of $316.02, indicating near-term buying pressure [3]. - The stock remains above its 20-day, 50-day, and 200-day SMAs of $311.37, $308.90, and $294.77 respectively, suggesting continued bullish momentum over medium and long-term time frames [3]. Group 2: Technical Indicators - The Moving Average Convergence Divergence (MACD) indicator at 2.70 points to bullish momentum building, while the Relative Strength Index (RSI) of 57.21 indicates that the stock is in neutral territory, neither overbought nor oversold [4]. - The technical setup suggests a stable uptrend with potential for further upside [4]. Group 3: Analyst Ratings - The consensus analyst rating for McDonald's stock is currently a Buy, with a price target of $323.25, indicating a potential upside of 5.25% based on recent ratings from Barclays, Baird, and Citigroup [5]. - The average price target from analysts is $333.33, suggesting further growth potential for the stock [5].

Eli Lilly And Co LLY will be reporting its first-quarter earnings on Thursday. Wall Street expects $3.05 in EPS and $12.67 billion in revenues as the company reports before market hours.The stock is up 14.35% over the past year, 14.79% YTD.Let’s examine the charts for Eli Lilly stock and how it currently compares to Wall Street estimates.Read Also: $1000 Invested In This Stock 20 Years Ago Would Be Worth This Much TodayLLY Stock Chart Strongly Bullish Ahead Of Q1 EarningsChart created using Benzinga ProEli ...

Core Viewpoint - The individual investor adopts a contrarian investment style, focusing on deep value opportunities, particularly in stocks that have recently experienced sell-offs due to non-recurrent events, while also considering insider buying as a positive signal [1] Investment Strategy - The investment portfolio is split approximately 50%-50% between shares and call options, indicating a balanced approach to risk and potential returns [1] - The investor's timeframe for holding positions typically ranges from 3 to 24 months, suggesting a medium-term investment horizon [1] - Fundamental analysis is employed to assess the health of companies, including their leverage and financial ratios compared to sector and industry averages [1] - Technical analysis is utilized to optimize entry and exit points, with a focus on support and resistance levels on weekly charts [1] Stock Selection Criteria - The investor screens for stocks that have undergone recent sell-offs, particularly when there is insider buying at the new lower price, indicating potential recovery [1] - Professional background checks are conducted on insiders who purchase shares post-sell-off, adding an additional layer of due diligence [1]

Investment Strategy - The company employs a contrarian investment style, focusing on high-risk, illiquid options and shares [1] - The investment portfolio is split approximately 50%-50% between shares and call options, with a typical investment timeframe of 3-24 months [1] - The company targets stocks that have recently experienced sell-offs due to non-recurrent events, particularly when insiders are buying shares at lower prices [1] Analysis Methodology - Fundamental analysis is utilized to assess the health of companies, including their leverage and financial ratios compared to sector and industry averages [1] - Professional background checks are conducted on insiders who purchased shares after sell-offs to ensure credibility [1] - Technical analysis is employed to optimize entry and exit points, using multicolor lines for support and resistance levels on weekly charts [1]

Core Viewpoint - The individual investor adopts a contrarian investment style, focusing on deep value opportunities, particularly in stocks that have recently experienced sell-offs due to non-recurrent events, while also considering insider buying as a positive signal [1] Investment Strategy - The investment portfolio is split approximately 50%-50% between shares and call options, indicating a balanced approach to risk and potential returns [1] - The investor's timeframe for holding positions typically ranges from 3 to 24 months, suggesting a medium-term investment horizon [1] - Fundamental analysis is employed to assess the health of companies, including their leverage and financial ratios compared to sector and industry averages [1] - Technical analysis is utilized to optimize entry and exit points, with a focus on support and resistance levels on weekly charts [1] Stock Selection Criteria - Preference is given to stocks that have undergone a recent sell-off, particularly when there is insider buying at the new lower price, indicating potential recovery [1] - The investor conducts professional background checks on insiders who purchase shares post-sell-off, adding a layer of due diligence to the investment process [1] Market Focus - The investor primarily screens stocks in the US market but is open to owning shares in less stable economies, referred to as "banana republics," indicating a willingness to explore diverse investment opportunities [1]

Investment Strategy - The company employs a contrarian investment style, focusing on high-risk, illiquid options and shares [1] - The investment portfolio is split approximately 50%-50% between shares and call options, with a typical investment timeframe of 3-24 months [1] - The company targets stocks that have recently experienced sell-offs due to non-recurrent events, particularly when insiders are buying shares at lower prices [1] Analysis Methodology - Fundamental analysis is utilized to assess the health of companies, including their leverage and financial ratios compared to sector and industry averages [1] - Professional background checks are conducted on insiders who purchased shares after sell-offs to ensure credibility [1] - Technical analysis is employed to optimize entry and exit points, using multicolor lines for support and resistance levels on weekly charts [1]

Core Viewpoint - NVIDIA and Qualcomm are both significant players in the chipmaking industry, showing signs of stabilization after recent declines, with potential for a shift in momentum [1] NVIDIA - NVIDIA shares are currently trading at $109, down nearly 30% from its all-time high in January, but signs indicate that the worst may be over, forming a double bottom pattern suggesting a bullish reversal [2] - The company reported record revenue with nearly 80% year-over-year growth in its latest earnings report, and forward guidance exceeded expectations, indicating strong demand for AI chips and data center hardware [4] - Despite the positive outlook, NVIDIA's shares have struggled to recover, yet analysts remain bullish, with Cantor Fitzgerald setting a price target of $220, indicating a potential 100% upside from current levels [5] - The stock has a high price-to-earnings (P/E) ratio of 38, which may deter value-focused investors [6] Qualcomm - Qualcomm shares are down over 30% from their high last June but have shown resilience, holding firm at a multi-year support line around $150, which could lead to stronger upward movements [7] - The last earnings report exceeded expectations and included a dividend increase, signaling confidence in future growth, although recent analyst upgrades have been limited [8] - Qualcomm's P/E ratio is significantly lower at 15.53, making it appear undervalued compared to NVIDIA and other peers, which may attract value investors [9] Investment Considerations - Both NVIDIA and Qualcomm present strong cases for investment heading into Q2, with NVIDIA offering growth potential and analyst attention, while Qualcomm provides a more grounded opportunity with better valuation and fundamentals [10] - Aggressive growth investors may prefer NVIDIA if it can maintain its current price levels, while those seeking value and lower risk may find Qualcomm to be the better option [11]